SON

Across TCGA pan-cancer cohorts, SON mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SON data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SON mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SON expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where SON mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.692	0.944	.002	31	view →
LUAD	OS	Tertile	III,IV	0.784	0.257	.012	16	view →
PDAC	DFS	Quartile	II,III,IV	0.204	0.466	.010	10	view →
LSCC	DFS	Median	All	0.796	0.635	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SON–HNSC (DFS)

Open the HNSC breakdown →